ERBB2 and neoplasm: According to the tumor biology, patients in the HER2-positive group had the highest rate of recurrence (50.0% of this group, n = 3), followed by the triple-negative group (30.4% of this group, n = 7), the luminal B HER2-positive group (28.6% of this group, n = 4), and the luminal B HER2-negative group (21.7% of this group, n = 5).